Martin Fortin

Martin Fortin

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
SSSøren T Skou
Søren T Skou
FMFrances S. Mair
Frances S. Mair
MFMartin Fortin
Martin Fortin
BGBruce Guthrie
Bruce Guthrie
BNBruno P. Nunes
Bruno P. Nunes
SSSusan M. Smith
Susan M. Smith

1 March 2012 in The Annals of Family Medicine
Verified
Journal Article
Closed access
PDF file
MFMartin Fortin
Martin Fortin
MSMoira Stewart
Moira Stewart
MPMarie-Eve Poitras
Marie-Eve Poitras
JAJosé Almirall
José Almirall
HMHeather Maddocks
Heather Maddocks
PURPOSE We sought to identify and compare studies reporting the prevalence of multimorbidity and to suggest methodologic aspects to be considered in the conduct of such studies. METHODS We searched the literature for English- and French-language articles published between 1980 and September 2010 that described the prevalence of multimorbidity in the general population, in primary care, or both. We assessed quality of included studies with a modified version of the Strengthening the Reporting of Observational Studies in Epidemiology checklist. Results of individual prevalence studies were adjusted so that they could be compared graphically. RESULTS The final sample included 21 articles: 8 described studies conducted in primary care, 12 in the general population, and 1 in both. All articles were of good quality. The largest differences in prevalence of multimorbidity were observed at age 75 in both primary care (with prevalence ranging from 3.5% to 98.5% across studies) and the general population (with prevalence ranging from 13.1% to 71.8% across studies). Apart from differences in geographic settings, we identified differences in recruitment method and sample size (primary care: 980–60,857 patients; general population: 1,099–316,928 individuals), data collection, and the operational definition of multimorbidity used, including the number of diagnoses considered (primary care: 5 to all; general population: 7 to all). This last aspect seemed to be the most important factor in estimating prevalence. CONCLUSIONS Marked variation exists among studies of the prevalence of multimorbidity with respect to both methodology and findings. When undertaking such studies, investigators should carefully consider the specific diagnoses included and their number, as well as the operational definition of multimorbidity.

17 May 2007 in BMJ
Verified
Journal Article
Closed access
PDF file
MFMartin Fortin
Martin Fortin
HSHassan Soubhi
Hassan Soubhi
CHCatherine Hudon
Catherine Hudon
EBElizabeth A Bayliss
Elizabeth A Bayliss
Marjan van den AkkerMarjan van den Akker
Marjan van den Akker
Time to focus on the needs of this vulnerable and growing population

17 April 2015 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
MTMarcello Tonelli
Marcello Tonelli
NWNatasha Wiebe
Natasha Wiebe
MFMartin Fortin
Martin Fortin
BGBruce Guthrie
Bruce Guthrie
BHBrenda R Hemmelgarn
Brenda R Hemmelgarn
FNFor The Alberta Kidney Disease Network
For The Alberta Kidney Disease Network
Multimorbidity is common and associated with poor clinical outcomes and high health care costs. Administrative data are a promising tool for studying the epidemiology of multimorbidity. Our goal was to derive and apply a new scheme for using administrative data to identify the presence of chronic conditions and multimorbidity. We identified validated algorithms that use ICD-9 CM/ICD-10 data to ascertain the presence or absence of 40 morbidities. Algorithms with both positive predictive value and sensitivity ≥70% were graded as “high validity”; those with positive predictive value ≥70% and sensitivity <70% were graded as “moderate validity”. To show proof of concept, we applied identified algorithms with high to moderate validity to inpatient and outpatient claims and utilization data from 574,409 people residing in Edmonton, Canada during the 2008/2009 fiscal year. Of the 40 morbidities, we identified 30 that could be identified with high to moderate validity. Approximately one quarter of participants had identified multimorbidity (2 or more conditions), one quarter had a single identified morbidity and the remaining participants were not identified as having any of the 30 morbidities. We identified a panel of 30 chronic conditions that can be identified from administrative data using validated algorithms, facilitating the study and surveillance of multimorbidity. We encourage other groups to use this scheme, to facilitate comparisons between settings and jurisdictions.

1 March 2006 in The Annals of Family Medicine
Verified
Journal Article
Closed access
PDF file
MFMartin Fortin
Martin Fortin
JDJonathan Dionne
Jonathan Dionne
GPGeneviève Pinho
Geneviève Pinho
JGJulie Gignac
Julie Gignac
JAJosé Almirall
José Almirall
LLLise Lapointe
Lise Lapointe
PURPOSE Many randomized controlled trials (RCTs) exclude patients who have multiple comorbidities. The aim of this study was to illustrate the prevalence of comorbidities among patients followed up in primary care who would have met the inclusion criteria of selected RCTs focusing on treatment of a particular condition. We used hypertension as an example of a particular chronic condition.

6 May 2010 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MFMartin Fortin
Martin Fortin
Catherine HudonCatherine Hudon
Catherine Hudon
JHJeannie Haggerty
Jeannie Haggerty
Marjan van den AkkerMarjan van den Akker
Marjan van den Akker
JAJosé Almirall
José Almirall
Published prevalence studies on multimorbidity present diverse data collection methods, sources of data, targeted age groups, diagnoses considered and study populations, making the comparability of prevalence estimates questionable. The objective of this study was to compare prevalence estimates of multimorbidity derived from two sources and to examine the impact of the number of diagnoses considered in the measurement of multimorbidity.